Sign in Subscribe
Pharmaceutical industry

Anadys Pharmaceuticals Inc. (ANDS) Investment Report: Potential Revenue of Over $500 Million with FDA Approval

Strategic Insights

— 1 min read

Anadys Pharmaceuticals Inc. (ANDS), a developer of novel therapies for the treatment of hepatitis C, has garnered attention from pharmaceutical companies and investors alike. The Company's lead candidate, ANA598, a non-nucleoside polymerase inhibitor, has shown promise in its phase II trial, with initial results expected by the fourth quarter of this year and further information anticipated in the first two quarters of 2010. If approved by the U.S. Food and Drug Administration (FDA), revenue for ANA598 could reach over $500 million at market saturation.

Key Takeaways:

  • Anadys Pharmaceuticals Inc. (ANDS) is a developer and marketer of novel therapies for the treatment of hepatitis C, focusing on under-served patients.
  • ANA598, the Company's lead candidate, is a non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV), currently in phase II trial.
  • The phase II trial has completed the ANA598 protocol, which includes combinations with pegylated interferon-alpha and ribaviran in patients with hepatitis C.
  • Initial results of the phase II trials are expected by the fourth quarter of this year, with further information expected during the first two quarters of 2010.
  • If approved by the FDA, revenue for ANA598 could reach over $500 million at market saturation, comparable to pharmaceutical companies such as Cephalon Inc. (Nasdaq:CEPH) and King Pharmaceuticals (Nasdaq:KG).
  • Pharmaceutical companies mentioned in the report include Dynavax Technologies Corp. (Nasdaq:DVAX), Gilead Sciences Inc. (Nasdaq:GILD), Human Genome Sciences Inc. (Nasdaq:HGSI), and Bristol-Myers Squibb Co. (NYSE:BMY).

Statistics:

  • $500 million: potential revenue for ANA598 at market saturation
  • $3.73 billion: market capitalization of Cephalon Inc. (Nasdaq:CEPH)
  • $2.04: stock price of Anadys Pharmaceuticals Inc. (ANDS) on 10-22-2008
  • $20.25: stock price of Bristol-Myers Squibb Co. (NYSE:BMY) on 10-29-2008
  • $1.97: stock price of Human Genome Sciences Inc. (Nasdaq:HGSI) on 11-13-2008

Sources:

  • GlobeNewswire via COMTEX (Aug 6, 2009)
  • BeaconEquity.com (http://www.beaconequity.com/i/ANDS)
  • Comtex SmarTrend Alert (http://www.mysmartrend.com)

Read more